Innovation Hub for Gene Therapies: London (GTVF)

The Kings College London Gene Therapy Vector Facility (GTVF) is a state-of-the-art facility established to support the scientific community in their delivery of the latest cutting-edge gene therapies into the clinic. With a legacy dating back to 2006, the GTVF is now one of the largest suppliers of GMP-grade viral vectors for clinical trials across Europe, offering: - Lentiviral vector - Retroviral vector - Adeno-associated viral vector (coming soon) The GTVF is run by a large, professionalised team of ~50 people who have extensive experience in delivering end-to-end viral vector manufacture for both academic and commercial clients, with a focus on early stage clinical activity. The GTVF is a core part of the London Innovation Hub for Gene Therapy (IHfGT), in partnership with University College London and London Royal Free. This brand new UK initiative is designed to advance the clinical development of new genetic treatments through the production of GMP (Good Manufacturing Practice) viral vectors. Find more information at https://www.genetherapyhubs.uk/.